Parkinson’s disease biomarkers: perspective from the NINDS Parkinson’s Disease Biomarkers Program

Journal Article · Mon May 01 04:00:00 EDT 2017 · Biomarkers in Medicine

DOI:https://doi.org/10.2217/bmm-2016-0370· OSTI ID:1598840

Gwinn, Katrina ^[1]; David, Karen K. ^[2]; Swanson-Fischer, Christine R. ^[2]; Albin, Roger L. ^[3]; Hillaire-Clarke, Coryse St ^[1]; Sieber, Beth-Anne ^[4]; Lungu, Codrin ^[2]; Bowman, DuBois ^[5]; Alcalay, Roy ^[5]; Babcock, Debra ^[6]; Dawson, Ted M. ^[7]; Dewey, Richard B. ^[8]; Foroud, Tatiana ^[9]; German, Dwight ^[8]; Huang, Xuemei ^[10]; Petyuk, Vladislav A. ^[11]; Potashkin, Judith ^[12]; Saunders-Pullamn, Rachel ^[13]; Sutherland, Margaret ^[1]; Walt, David R. ^[14] ; West, Andrew ^[15]; Zhang, Jing ^[11]; Chen-Plotkin, Alice ^[16]; Scherzer, Clemens R. ^[17]; Vaillancout, David ^[18]; Rosenthal, Liana S. ^[7]

---

1. NIH
2. National Institute of Neurological Disorders & Stroke
3. University of Michigan
4. National Institutes of Health
5. Columbia University
6. National Institute of Neurological Diseases and Stroke, National Institutes of Health
7. Johns Hopkins University
8. University of Texas at Dallas
9. Indiana University - Purdue University at Indianapolis
10. Pennsylvania State University
11. BATTELLE (PACIFIC NW LAB)
12. Rosalind Franklin University of Medicine and Sciences
13. Department of Neurology, Mount Sinai Beth Israel & Icahn School of Medicine
14. Tufts University
15. University of Alabama - Birmingham
16. University of Pennsylvania
17. Brigham and Women's Hospital
18. University of Florida

Biomarkers for Parkinson’s disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson’s Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.

• Research Organization: Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
• Sponsoring Organization: USDOE
• DOE Contract Number: AC05-76RL01830
• OSTI ID: 1598840
• Report Number(s): PNNL-SA-129861
• Journal Information: Biomarkers in Medicine, Journal Name: Biomarkers in Medicine Journal Issue: 6 Vol. 11
• Country of Publication: United States
• Language: English